1. General properties of LAFTI strains in vitro Relatively good survival in conditions of the human GI tract (low pH, bile acids) Inhibit pathogenic bacteria in vitro (E. coli, Salmonella, Listeria, Staphylococcus aureus and Clostridia) Good adhesion to intestinal mucus Good survival in most delivery vehicles

2. Example on in vivo assessment of efficacy Orogastric dosage (probiotics) Challenge (pathogen) Collect faecal pellets Enumeration of faecal pathogen Monitoring faecal levels of pathogen and loss of body weight against pathogen colonization Protection against pathogen colonization

3. Protection against salmonellae Henriksson and Conway (2001) Journal of Applied Microbiology, 90:223-228

4. Progress of Salmonella infection * ** * Henriksson and Conway (2001) Journal of Applied Microbiology, 90:223-228; ** Amansec et al (2000) ASM conference, Cairns, Australia *

5. LAFTI® protects against Salmonella Henriksson et al. (2002) IDF conference, Paris

6. Inhibition of Listeria in the GI tract Mahoney et al. (2003) International Journal of Food Microbiology 84:255-261

7. Inhibition of Listeria in vitro Mahoney et al. (2003) International Journal of Food Microbiology (in press) 84:255-261

8. LAFTI® reduces incidence of cancer ControlLAFTI TM L10GG Incidence of tumour formation (%) 401520 Large intestinal tumours (no.) 103131 4 Tumour mass index (log 10 ) 1.70.1 2 1.9 1 statistically different from the control at 5% level (Chi test); 2statistically different from all other treatments (P<0.05) McIntosh et al. (1999) Nutrition and Cancer 35:153-159

9. Survival of LAFTI® L10 in comparison with other strains (in a gastrointestinal model) 9

10. Effect of LAFTI® L10 on gut disturbances (UNSW) Placebo controlled, randomized, cross-over study Subjects (n = 60) treated with LAFTI® L10, Lactobacillus sp. and placebo for 2 weeks Two weeks wash out between treatments Questionnaires completed at the end of each treatment week

11. How treatment with LAFTI® was perceived Do you think that the capsules have a beneficial effect? Welin et al, UNSW, evaluation completed Q42003 * * Significantly different from the placebo (P < 0.05)

12. LAFTI® L10 reduces gastrointestinal disturbances Have you experienced any of the following gut disturbances while taking the capsules? (circle the number that best describes the severity of the condition: 1 = low, 10 = severe). Welin et al, UNSW, evaluation completed Q42003 * Significantly different from the placebo (P < 0.03)

13. LAFTI ® inhibit Listeria monocytogenes Control (starter only) Starter + Probiotic cultures Pidcock et al. (2002) International Journal of Food Microbiology 76:75-81

14. Important properties of LAFTI® Are perceived as having a beneficial effect on general human health (L10) Alleviate symptoms of a wide range of gut disturbances (L10) Survive in the human GI tract (L10, L26 and B94) Reduce survival of Listeria in the GI tract of animals (L10) Inhibit a range of pathogenic bacteria in vitro (L10, L26 and B94) Reduce severity of Salmonella infections in animals (L26 and B94) Protect against small and large intestinal cancers in animals (L10) Utilize a range of prebiotics (B94) Folate producing (B94) Produce antihypertensive peptides (L10, L26 and B94) Produce lactase (L10, L26 and B94) Good survival in capsules and in a range of different foods (L10, L26 and B94) Contribute to increased food safety (L10, L26 and B94)